-
Sep 24, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoSeptember 24, 2024Author(s):Medical experts discuss considerations and patient guidance for oral and IV HMAs.Video content above is prompted by the following:What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient preferences?
-
Sep 24, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoSeptember 24, 2024Author(s):Medical experts offer their insights and closing remarks regarding patient feedback for MDS. Video content above is prompted by the following:How do you address challenges related to medication adherence in patients with myelodysplastic syndromes (MDS) receiving oral decitabine-cedazuridine, and what strategies or tips have you found effective in promoting adherence to treatment regimens?
-
Sep 17, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoSeptember 17, 2024Author(s):Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.Video content above is prompted by the following:From a patient’s perspective, what are some of the advantages and disadvantages of using oral hypomethylating agents (HMAs) vs injectable HMAs?
-
Sep 17, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoSeptember 17, 2024Author(s):Medical experts discuss innovations and future directions in treatments for higher-risk MDS. Video content above is prompted by the following:What are the key challenges in developing effective therapies for patients with TP53-mutated higher-risk myelodysplastic syndromes (MDS), and what strategies are being explored to address these challenges? What innovations in the pipeline for higher-risk MDS treatments are you most excited about?
-
Sep 10, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoSeptember 10, 2024Author(s):Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS. Video content above is prompted by the following:What insights do you have on the persistence and effectiveness of hypomethylating agents in patients with higher-risk myelodysplastic syndromes, and how do these data inform treatment decisions?
-
Sep 10, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoSeptember 10, 2024Author(s):Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.Video content above is prompted by the following:For patients with higher-risk myelodysplastic syndromes (MDS), what are some of the primary challenges in conducting research and developing novel therapies for this patient population?
-
Sep 3, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoSeptember 3, 2024Author(s):Medical experts discuss the data gathered from the ASCERTAIN trial. Video content above is prompted by the following:Although oral decitabine-cedazuridine has been FDA approved for some time, the ASCERTAIN trial data are a recent advancement in our knowledge of this drug and its use in myelodysplastic syndromes (MDS). Briefly describe the ASCERTAIN trial design.
-
Sep 3, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
Video content above is prompted by the following:• Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.
-
Aug 27, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoAugust 27, 2024Author(s):After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding. Video content above is prompted by the following:How has the new WHO (5th edition and ICC classification scheme for MDS impacted our understanding and management, particularly in distinguishing lower and higher risk categories?
-
Aug 27, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoAugust 27, 2024Author(s):Medical experts discuss risk-based approaches to choosing MDS therapies. Video content above is prompted by the following:Provide a high level overview of treatment approaches for both lower and higher risk MDS. What are the key considerations when selecting between different treatment options for lower risk MDS? Please include a discussion of when hypomethylating agents (HMAs) would be used in lower risk disease.
